Cargando…
Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis
The Pharmaceuticals and Medical Devices Agency (PMDA) has approved hundreds of new drugs in recent years. We retrospectively analyzed the new drugs approved in Japan from 2008 to 2019, and identify the first‐in‐world approvals and clarify the current drug lag. The new drug and the drug lag were defi...
Autores principales: | Tanaka, Mototsugu, Idei, Mayumi, Sakaguchi, Hiroshi, Kato, Ryosuke, Sato, Daisuke, Sawanobori, Kenji, Kawarasaki, Shuichi, Hata, Toshiyuki, Yoshizaki, Asako, Nakamura, Miki, Ikuma, Mutsuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246743/ https://www.ncbi.nlm.nih.gov/pubmed/33048367 http://dx.doi.org/10.1002/cpt.2080 |
Ejemplares similares
-
Conditional early approval for new drug applications in Japan: Current and emerging issues
por: Tanaka, Mototsugu, et al.
Publicado: (2023) -
Assessment of the impact of Japanese‐specific long‐term safety data on new drug approval
por: Uzu, Shinobu, et al.
Publicado: (2021) -
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics
por: Ebata, Satoshi, et al.
Publicado: (2022) -
Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States
por: Cho, Inhye, et al.
Publicado: (2022) -
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)